Engene TherapeuticsENGN
13F holders, Q1 2026 (March 31)2holders
$6.81avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Engene Therapeutics Inc. (ENGN) in their 13F filings. The largest holders were Marshall Wace, LLP ($2.3M) and SBI Securities Co., Ltd. ($191).
- Company
- Engene Therapeutics Inc.
- CUSIP
- 29286X101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $2.3M |
| Exits | 0 | $0 |
Ownership 2 holders
| Marshall Wace, LLP | 0.00% | New | 343,928 | $2.3M |
| SBI Securities Co., Ltd. | 0.00% | New | 28 | $191 |
"% of holder's portfolio" is ENGN's weight in each manager's 13F, not the share of Engene Therapeutics Inc. the manager owns.